170 related articles for article (PubMed ID: 23081669)
1. Flow cytometric determination of stem/progenitor content in epithelial tissues: an example from nonsmall lung cancer and normal lung.
Donnenberg VS; Landreneau RJ; Pfeifer ME; Donnenberg AD
Cytometry A; 2013 Jan; 83(1):141-9. PubMed ID: 23081669
[TBL] [Abstract][Full Text] [Related]
2. Statistical classification of multivariate flow cytometry data analyzed by manual gating: stem, progenitor, and epithelial marker expression in nonsmall cell lung cancer and normal lung.
Normolle DP; Donnenberg VS; Donnenberg AD
Cytometry A; 2013 Jan; 83(1):150-60. PubMed ID: 23239514
[TBL] [Abstract][Full Text] [Related]
3. KIT (CD117) expression in a subset of non-small cell lung carcinoma (NSCLC) patients.
Donnenberg AD; Zimmerlin L; Landreneau RJ; Luketich JD; Donnenberg VS
PLoS One; 2012; 7(12):e52885. PubMed ID: 23285214
[TBL] [Abstract][Full Text] [Related]
4. Value of cytokeratin 5/6 immunostaining in distinguishing epithelial mesothelioma of the pleura from lung adenocarcinoma.
Ordóñez NG
Am J Surg Pathol; 1998 Oct; 22(10):1215-21. PubMed ID: 9777983
[TBL] [Abstract][Full Text] [Related]
5. Tumorigenic stem and progenitor cells: implications for the therapeutic index of anti-cancer agents.
Donnenberg VS; Landreneau RJ; Donnenberg AD
J Control Release; 2007 Oct; 122(3):385-91. PubMed ID: 17582641
[TBL] [Abstract][Full Text] [Related]
6. Prognostic value of cancer stem cells, epithelial-mesenchymal transition and circulating tumor cells in lung cancer.
Pirozzi G; Tirino V; Camerlingo R; La Rocca A; Martucci N; Scognamiglio G; Franco R; Cantile M; Normanno N; Rocco G
Oncol Rep; 2013 May; 29(5):1763-8. PubMed ID: 23426441
[TBL] [Abstract][Full Text] [Related]
7. The significance of bivariate cytokeratin and DNA flow cytometry in paraffin-embedded specimens of non-small cell lung cancer.
Otsuka H; Funai S; Tsuda H; Azumi T; Hara S; Okuno K; Yasutomi M
Int J Clin Oncol; 2001 Oct; 6(5):229-35. PubMed ID: 11723744
[TBL] [Abstract][Full Text] [Related]
8. Trivariate flow cytometric analysis of paraffin-embedded lung cancer specimens: application of cytokeratin subtype specific antibodies to distinguish between differentiation pathways.
Leers MP; Theunissen PH; Koudstaal J; Schutte B; Ramaekers FC
Cytometry; 1997 Feb; 27(2):179-88. PubMed ID: 9012385
[TBL] [Abstract][Full Text] [Related]
9. The role of CD133 expression in the carcinogenesis and prognosis of patients with lung cancer.
Le H; Zeng F; Xu L; Liu X; Huang Y
Mol Med Rep; 2013 Nov; 8(5):1511-8. PubMed ID: 24008862
[TBL] [Abstract][Full Text] [Related]
10. Localization of CD44 and CD90 positive cells to the invasive front of breast tumors.
Donnenberg VS; Donnenberg AD; Zimmerlin L; Landreneau RJ; Bhargava R; Wetzel RA; Basse P; Brufsky AM
Cytometry B Clin Cytom; 2010 Sep; 78(5):287-301. PubMed ID: 20533389
[TBL] [Abstract][Full Text] [Related]
11. Ability of bivariate cytokeratin and deoxyribonucleic acid flow cytometry to determine the biologic aggressiveness of resectable non-small cell lung cancer.
Otsuka H; Funai S; Azumi T; Hara S; Okuno K; Yasutomi M
J Thorac Cardiovasc Surg; 2002 Aug; 124(2):293-8. PubMed ID: 12167789
[TBL] [Abstract][Full Text] [Related]
12. Mesenchymal stem cells, therapy, and cytometry.
Donnenberg VS; Ulrich H
Cytometry A; 2013 Jan; 83(1):8-10. PubMed ID: 23281002
[No Abstract] [Full Text] [Related]
13. P63 in pulmonary epithelium, pulmonary squamous neoplasms, and other pulmonary tumors.
Wang BY; Gil J; Kaufman D; Gan L; Kohtz DS; Burstein DE
Hum Pathol; 2002 Sep; 33(9):921-6. PubMed ID: 12378518
[TBL] [Abstract][Full Text] [Related]
14. Cell surface marker profiling of human tracheal basal cells reveals distinct subpopulations, identifies MST1/MSP as a mitogenic signal, and identifies new biomarkers for lung squamous cell carcinomas.
Van de Laar E; Clifford M; Hasenoeder S; Kim BR; Wang D; Lee S; Paterson J; Vu NM; Waddell TK; Keshavjee S; Tsao MS; Ailles L; Moghal N
Respir Res; 2014 Dec; 15(1):160. PubMed ID: 25551685
[TBL] [Abstract][Full Text] [Related]
15. Bivariate cytokeratin/DNA flow cytometric analysis of paraffin-embedded samples from colorectal carcinomas.
Leers MP; Theunissen PH; Schutte TB; Ramaekers FC
Cytometry; 1995 Sep; 21(1):101-7. PubMed ID: 8529463
[TBL] [Abstract][Full Text] [Related]
16. Differential diagnostic value of CD5 and CD117 expression in thoracic tumors: a large scale study of 1465 non-small cell lung cancer cases.
Kriegsmann M; Muley T; Harms A; Tavernar L; Goldmann T; Dienemann H; Herpel E; Warth A
Diagn Pathol; 2015 Dec; 10():210. PubMed ID: 26643918
[TBL] [Abstract][Full Text] [Related]
17. Analysis of circulating tumor cells in patients with non-small cell lung cancer using epithelial marker-dependent and -independent approaches.
Krebs MG; Hou JM; Sloane R; Lancashire L; Priest L; Nonaka D; Ward TH; Backen A; Clack G; Hughes A; Ranson M; Blackhall FH; Dive C
J Thorac Oncol; 2012 Feb; 7(2):306-15. PubMed ID: 22173704
[TBL] [Abstract][Full Text] [Related]
18. Cell kinetic analysis of mixed populations using three-color fluorescence flow cytometry.
Begg AC; Hofland I
Cytometry; 1991; 12(5):445-54. PubMed ID: 1718673
[TBL] [Abstract][Full Text] [Related]
19. Quantification of PD-L1 and PD-1 expression on tumor and immune cells in non-small cell lung cancer (NSCLC) using non-enzymatic tissue dissociation and flow cytometry.
Chargin A; Morgan R; Sundram U; Shults K; Tsay EL; Ratti N; Patterson BK
Cancer Immunol Immunother; 2016 Nov; 65(11):1317-1323. PubMed ID: 27565980
[TBL] [Abstract][Full Text] [Related]
20. The role of CD133 in the identification and characterisation of tumour-initiating cells in non-small-cell lung cancer.
Tirino V; Camerlingo R; Franco R; Malanga D; La Rocca A; Viglietto G; Rocco G; Pirozzi G
Eur J Cardiothorac Surg; 2009 Sep; 36(3):446-53. PubMed ID: 19464919
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
